Evogene Advances BMC128 Therapy in Phase 1 Study for Advanced Solid Tumors

Evogene Ltd. (EVGN) announces a significant advancement in its clinical research with the successful completion of a Phase 1 study for BMC128, a microbiome therapy developed by its subsidiary, Biomica Ltd.

Milestone Achievement in Cancer Therapy

This study, which focuses on patients with advanced solid tumors who have previously shown progression after anti-PD-1 treatments, represents a pivotal step in understanding the potential benefits of combining BMC128 with Nivolumab, a standard immunotherapy.

The study, which involved 11 patients with various cancers including melanoma and renal cell carcinoma, achieved its primary aim of establishing safety and tolerability without any dose-limiting toxicities, offering a promising outlook for future applications in immuno-oncology.

Encouraging Preliminary Results

Throughout the clinical trial, patients first underwent a two-week period of BMC128 monotherapy followed by a 16-week combination therapy with Nivolumab.

The preliminary data is encouraging, demonstrating early signs of anti-tumor activity, with five out of eleven participants achieving stable disease status during and after treatment.

Future Prospects for BMC128

Evogene's President and CEO, Ofer Haviv, highlights the completion of this study as a significant milestone in the development of BMC128.

Following these promising results, Evogene has entered into a licensing agreement with Lishan Biotech for the continued advancement of BMC128, now referred to as LS-LBP-002.

Dr. Weijie Chen from Lishan Biotech expressed enthusiasm regarding these findings and indicated plans for expedited clinical development.